A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants

计划入组 104 人 · 首次发布于 2026 年 2 月 19 日

M3541 in Combination With Radiotherapy in Solid Tumors

计划入组 15 人 · 首次发布于 2017 年 7 月 21 日

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

计划入组 65 人 · 首次发布于 2022 年 5 月 5 日

ML241

Lu-AF-33241

BB-3241

Meiji Seika Pharma Launches Phase I Trial of ME3241, Novel PD-1 Agonist for Autoimmune Diseases